- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04388735
Multiple Myeloma (MM) Quality of Life (QOL) Study
Quality of Life and Psychological Distress in Patients With Multiple Myeloma and Their Caregivers
The main purpose of this study is to examine differences in quality of life and psychological distress for both Multiple Myeloma patients receiving treatment and their caregivers and to assess patient and caregiver prognostic understanding (understanding of the likely course of a disease over time) of Multiple Myeloma to guide development of more personalized treatment plans.
This study looks to further understand quality of life changes throughout multiple myeloma therapy for both patients and caregivers to help determine ways to improve patient and caregiver understanding of illness and in turn, tailor customized treatment that best aligns with patient preferences.
The study will use a series of questionnaires to measure quality of life, mood, coping strategies, and prognostic understanding.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
- It is expected that about 180 people undergoing treatment for multiple myeloma and up to 180 of their caregivers will take part in this research study.
-- The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Elizabeth K O'Donnell, MD
- Phone Number: 617-643-2517
- Email: ekodonnell@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Contact:
- Jacalyn Rosenblatt, MD
- Phone Number: 617-667-9920
- Email: jrosenb1@bidmc.harvard.edu
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Principal Investigator:
- Omar Nadeem, MD
-
Contact:
- Omar Nadeem, MD
- Phone Number: 617-658-6000
- Email: Omar_Nadeem@dfci.harvard.edu
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Cancer Center
-
Principal Investigator:
- Elizabeth K O'Donnell, MD
-
Contact:
- Elizabeth K O'Donnell, MD
- Phone Number: 617-643-2517
- Email: ekodonnell@mgh.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patient Eligibility criteria:
Adult patients (greater than 18 years) receiving active therapy for MM.
- For patients with newly diagnosed MM, patients are eligible while undergoing induction therapy prior to received autologous stem cell transplant but not after.
- Ability to read questions in English or willing to complete questionnaires with the assistance of an interpreter.
Caregiver Eligibility criteria:
- Adult (greater than 18 years) relative or a friend of a patient who agrees to participate in the study whom the patient identified as living with them or having in-person contact with him or her at least twice per week.
- Ability to read and respond to questions in English or to complete questionnaires with minimal assistance of an interpreter
Exclusion Criteria:
Patient Exclusion criteria:
- Patients receiving maintenance therapy only.
- Significant psychiatric or other co-morbid disease, which the treating clinician believes prohibits informed consent or participation in the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Newly Diagnosed MM 1st Line and Caregivers
This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
|
Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
|
MM receiving 1-3 prior lines of therapy and Caregivers
This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
|
Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
|
MM patients receiving ≥ 4 lines of therapy and Cargivers
This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
|
Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life (QOL) Patient Description
Time Frame: Up to 1 year
|
Describe patient QOL scores by lines of therapy.
Functional Assessment of Cancer Therapy-Multiple Myeloma(FACT-MM) will be used to assess QOL, which has been validated for use in multiple care settings.[10].
The FACT-MM consists of four subscales assessing well-being across four domains (physical, functional, emotional, and social).
These self-reported measures possess strong psychometric properties and have been validated for patients with cancer [Appendix E].
|
Up to 1 year
|
Quality of life (QOL) Caregiver Description
Time Frame: Up to 1 year
|
Describe cargiver QOL scores by associated patient line of therapy
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QOL-Functional Assessment
Time Frame: Up to 1 year
|
Describe and compare patient QOL Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) scores by line of therapy.
The FACT-MM consists of four subscales assessing well-being across four domains (physical, functional, emotional, and social).
These self-reported measures possess strong psychometric properties and have been validated for patients with cancer
|
Up to 1 year
|
Patient Burden Assessment-ESAS
Time Frame: Up to 1 year
|
Describe and compare patient symptoms (ESAS) scores by line of therapy.
The Edmonton Symptom Assessment System (ESAS) will be used to ascertain the symptom burden experienced by patients.
This previously validated survey assesses nine symptoms frequently reported by patients with cancer: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath [
|
Up to 1 year
|
Patient Fatigue Symptoms
Time Frame: Up to 1 year
|
Describe and compare patient fatigue symptoms (FACIT-Fatigue) by line of therapy. The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue), a 13-item FACIT subscale specific to fatigue that measures an individual's level of fatigue during their usual daily activities over the past week.[13, 14] The level of fatigue is measured on a 4-point Likert scale . |
Up to 1 year
|
Patient anxiety symptoms
Time Frame: Up to 1 year
|
Describe and compare patient anxiety and depression symptoms Hospital Anxiety and Depression Scale (HADS) to assess symptoms of depression and anxiety in all study participants.
The HADS is a 14-item questionnaire that contains two 7-item subscales assessing depression and anxiety symptoms during the past week.. Scores on each subscale range from 0 to 21, with a cutoff of 8 or greater denoting clinically significant anxiety or depression
|
Up to 1 year
|
Patient Depression symptoms
Time Frame: Up to 1 year
|
Describe and compare patient anxiety and depression symptoms Hospital Anxiety and Depression Scale Hospital Anxiety and Depression Scale (HADS) to assess symptoms of depression and anxiety in all study participants.
The HADS is a 14-item questionnaire that contains two 7-item subscales assessing depression and anxiety symptoms during the past week.. Scores on each subscale range from 0 to 21, with a cutoff of 8 or greater denoting clinically significant anxiety or depression
|
Up to 1 year
|
Patient Post-traumatic stress symptoms
Time Frame: Up to 1 year
|
Describe and compare post-traumatic stress symptoms (PCL-C) by line of therapy The Post-Traumatic Stress Disorder Checklist (PCL) to assess symptoms of post-traumatic stress in patients and caregivers.
The PCL is a 17 item self-reported measure that evaluates symptoms of post traumatic stress disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders-IV
|
Up to 1 year
|
Patient coping
Time Frame: Up to 1 year
|
Describe and compare patient coping (Brief Cope) by line of therapy.
The Brief Cope, a 28-item questionnaire that assess 14 methods of coping (e.g., self-distraction, humor, denial) using a 4-point Likert scale
|
Up to 1 year
|
Caregiver Quality of Life (QOL)
Time Frame: Up to 1 year
|
Describe and compare caregiver burden and QOL (CARGOQOL) scores by line of therapy.
CareGiver Oncology QOL questionnaire (CARGOQOL) will be used to measure caregiver QOL.
The CarGOQOL is a 29-item well-validated instrument to measure QOL in multiple domains.
|
Up to 1 year
|
Caregiver Burden
Time Frame: Up to 1 year
|
Describe and compare caregiver burden and QOL (CARGOQOL) scores by line of therapy.
CareGiver Oncology QOL questionnaire (CARGOQOL) will be used to measure caregiver QOL.
The CarGOQOL is a 29-item well-validated instrument to measure QOL in multiple domains.
|
Up to 1 year
|
Caregiver anxiety
Time Frame: Up to 1 year
|
Describe and compare caregiver anxiety and depression symptoms (caregiver HADS) by line of therapy.
The Hospital Anxiety and Depression Scale will be used to (HADS) to assess symptoms of depression and anxiety in all study participants (patients and family caregivers).
The HADS is a 14-item questionnaire that contains two 7-item subscales assessing depression and anxiety symptoms during the past week.
Scores on each subscale range from 0 to 21, with a cutoff of 8 or greater denoting clinically significant anxiety or depression
|
Up to 1 year
|
Caregiver Depression
Time Frame: Up to 1 year
|
Describe and compare caregiver anxiety and depression symptoms (caregiver HADS) by line of therapy.
The Hospital Anxiety and Depression Scale will be used to (HADS) to assess symptoms of depression and anxiety in all study participants (patients and family caregivers).
The HADS is a 14-item questionnaire that contains two 7-item subscales assessing depression and anxiety symptoms during the past week. .
Scores on each subscale range from 0 to 21, with a cutoff of 8 or greater denoting clinically significant anxiety or depression
|
Up to 1 year
|
Caregiver Coping
Time Frame: Up to 1 Year
|
Describe and compare caregiver coping (Brief Cope) Brief Cope, a 28-item questionnaire that assess 14 methods of coping (e.g., self-distraction, humor, denial) using a 4-point Likert scale
|
Up to 1 Year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth K O'Donnell, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Behavioral Symptoms
Other Study ID Numbers
- 19-816
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Questionnaire
-
H. Lee Moffitt Cancer Center and Research InstituteSan Diego State University; University of Minnesota; University of ArizonaCompletedAnxiety | Psychological StressUnited States
-
Centre Hospitalier Universitaire de NiceCompletedGeneral Population | TDAH | Children Aged 5 to 18 YearsFrance
-
Minneapolis Veterans Affairs Medical CenterUnited States Department of DefenseCompletedLower Limb Amputation Below Knee (Injury) | Lower Limb Amputation Above Knee (Injury)United States
-
NSABP Foundation IncNational Cancer Institute (NCI)Completed
-
Imperial College LondonRoyal Marsden NHS Foundation Trust; University College London Hospitals; The... and other collaboratorsCompleted
-
Stanford UniversityRecruitingAstigmatism | Nearsightedness | FarsightednessUnited States
-
University of LiegeCompletedCritical Illness | Covid19 | Psychological Stress | FamilyBelgium
-
Imperial College Healthcare NHS TrustNot yet recruitingCervical Myelopathy
-
Rabin Medical CenterCompleted
-
National Taiwan University HospitalNational Taiwan UniversityUnknownComputerized Physician Order EntryTaiwan